Â鶹ӳ»­

Many patients with advanced ovarian cancer treated with frontline therapies still end up with clinically undetectable amounts of cancer cells afterward, called minimal residual disease (MRD), leading to high likelihood of recurrence. However, there are no reliable tests to detect MRD, and its biological features remain understudied. Residual cancer cells escape the effects of surgery and chemotherapy and are the reason why cure rates...